Jerusalem Post, 25/1/2012 - Delek Real Estate nears bondholders settlement
Bondholders are still deliberating, though, whether to accept or reject the offer.

Globes, 25/1/2012 - Delek Real Estate keeps its options open
Yitzhak Tshuva is waiting till the last moment to decide the company's fate: a debt settlement, or a petition for a stay of proceedings.

TheStreet*, 25/1/2012 - Roche's Illumina Bid May Start War
NEW YORK (TheStreet) -- With news breaking late on Tuesday of Roche's hostile $5.7 billion offer for Illumina, M&A watchers would be wise to remember a similar-sized deal that eventually turned a hostile and resulted in a new buyer and a 20% price increase. In March, 2011, Valeant Pharmaceuticals took a $5.7 billion bid for Cephalon directly to the company shareholders after management called the offer "opportunistic" and talks stalled. The move caused shares to surge above the $73 a share bid price. While the bid eventually failed , optimistic investors were vindicated by a $6.8 billion competing bid from Teva Pharmaceuticals, which valued the company at $81.50 a share. ... Click to view a price quote on ILMN. Click to research the Drugs industry.

Globes, 24/1/2012 - Hapoalim raises credit margin for contractors
"Bank Leumi has already stopped lending to real estate, and Bank Hapoalim is exploiting the credit crunch to raise prices."